Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Syria rejects forced deportations from Germany amid migration debate - 2German inflation soars to 2.7% in March as Iran war drives up prices
- 3Insane Realities That Will Make You Reconsider How you might interpret History
- 4With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
- 5Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- Audits of the Top Science fiction Movies This Year
- My Excursion to Monetary Autonomy: Awesome ways to save cash
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Instructions to Floss Appropriately and Forestall Gum Sickness
- Behind every perfect holiday memory is a mom on the brink
- Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
- Figuring out the Justification for Separation: To blame and No-Shortcoming
